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The early bactericidal activity (EBA) of ethambutol,
pyrazinamide and the fixed combination of isoniazid,
rifampicin and pyrazinamide (Rifater. Mer National) was
evaluated in patients with pulmonary tuberculosis who
were sputum-positive on microscopy for acid-fast bacilli.
Twenty-eight patients (mean age 33 years and weight
51 kg on average; range 40 - 59 kg) were studied. The fall
in viable counts of Mycobacterium tuberculosis in sputum
collections during the 2 days following the start of
treatment was estimated from counts of colony-fonning
units (CFUs) of M. tuberculosis per ml of sputum cultured
on selective 7H1 0 agar medium. The EBA for ethambutol
determined in 9 patients was 0.245 ± 0.046, log" CFUlml
sputum/day, that for pyrazinamide was 0.003 ± 0.014 log"
CFU/ml sputum/day and that for Aifater 0.558 ± 0.054 log"
CFU/ml sputum/day. The results obtained are similar to
those reported in a previous study of the first 2 days of
treatment, but in smaller numbers of patients, and confirm
the moderate EBA of ethambutol while pyrazinamide is
again shown to have very littJe EBA. Rifater has a marked
EBA which may be due mainly to the action of isoniazid.
This methodology may be vatuable in the rapid evatuation
of the bactericidat activity of new antituberculosis agents
and the comparison of different dose sizes of agents of
the same class.
S Air Med J 1996; 86: 155-158.
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Following the initiation of antituberculosis therapy, there is a
rapid fall in the number of viable tubercle bacilli in the
sputum of patients with pulmonary tuberculosis.' When
quantified by means of serial counts of colony-forming units
(CFU) of Mycobacterium tuberculosis in sputum, significant
differences in bactericidal action between different
antituberculosis agents have been found during the first 2
days of treatment.2 As most of the organisms killed during
this period are probably extracellular. actively metabolising
and in a logarithmic phase of muttiplication. estimation of
this early bactericidal activity (EBA) may provide an in vivo
estimation of the bactericidal capacity of different
antituberculosis drugs and a comparison of the activity of
various dose sizes of agents of the same class.
Comparisons between the EBA of rifabutin and rifampicin
have been made in two more recent studies. 3,~
In the first stUdy of EBA. undertaken in Nairobi, 27 agents
alone or in combination were studied, usuatly in groups of
only 4 patients.2 We report here a further confinnatory study
of the EBA of ethambutol and pyrazinamide and of the fixed
combination of isoniazid, rifampicin and pyrazinamide
(Aifater; Mer National) in the dosages used during routine
chemotherapy in 50uth Africa.
Material and methods
Patients
Twenty-eight patients with previously untreated pulmonary
tuberculosis whose sputum was positive for acid-fast bacilli
on microscopy were studied. Patients were between 18 and
60 years of age (mean 33 years; median 44 years) and
weighed 51 kg on average (range 40 - 59 kg).
In 25 patients (89%), mutticavitary disease was present
which in 24 (86% )involved an area larger than the right
upper lobe. None of the patients suffered from other
complicating medical conditions and none of the women
was pregnant.
Patients were allocated consecutiveiy to groups receiving
dally doses of ethambutol 1.2 g, pyrazinamide 2 g, or fixed-
combination tablets (Rifater) each containing isoniazjd
80 mg, rifampicin 120 mg and pyrazinamide 250 mg,
administered in a dose of 1 tablet for every 10 kg body
weight. At the conclusion of the study, patients were placed
on the treatment regimen currently recommended by the
South African Tuberculosis Control Programme, Le.
isoniazid, rifampicin and pyrazinamide for 6 months.
A 16-hour collection of sputum was made between 16hOO
on day 1 and 08hOO the next day (51). After the first
collection was complete, the first drug dose was
administered at least 60 minutes before breaidasl and this
procedure was repeated twice more on SUbsequent days to
give 82 and 53 sputum collections. This procedure is
summarised in Rg. 1. Because of the slew onset of
bactericidal activity in the case of pyrazinamide.' a third
dose of the drug was given followed by an 54 sputum
collection. Sputum specimens were sent by air courier to
Pretoria for analysis In the laboratories of the South African
National Tuberculosis Aesearch Programme.
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Fig. 1. Procedure for collection of sputum specimens 51, 52 and
53 and administration of antituberculosis agents.
Microbiological evaluation
Conventional smear. cutture, sensitivity testing and CFU
count were carried out as described previously except that
after 2 ml homogenised sputum were mixed with 3 m11:10
dithiothreitol (Sputolysin: Hoechst), 20 ~I of the dilutions
were set up without preliminary centrifugation on duplicate
slopes of selective 7H10 medium in universal 28 ml screw-
capped containers for CFU counting. Statistical evaluation
was by means of (-tests.
The study protocol was approved by the Ethical
























Fig. 2. Colony counts of M. fuberculosis in sputum in three
groups of 9 patients each with pulmonary tuberculosis during the
first 2 days of treatment with Rifater and with ethambutol and
pyrazinamide. Interrupted lines represent mean values.
(Rifater) group was 0.558 log" CFU/mVday (± 0.054), the
highest found; n: can be compared with 0.685 10910
CFU/mVday for the group in the Nairobi study that received
A total of 35 patients was studied of whom 7 were excluded,
6 because they had negative or contaminated cuttures and 1
because of initial drug resistance. The viable counts in the
sputum collections from the remaining 28 patients obtained
before chemotherapy (S1) and at daily intervals thereafter
(52 and $3) are given as means in Table I and illustrated for
individual patients in Fig. 2. In patients given Rifater. there
was only a slight fall on the first day of treatment (day 0 to
day 1) but a large and abrupt fall the next day (day 1 to day
2). indicating a delay before the start of the bactericidal
activity of the combination. The counts of patients given
ethambutol declined slowly and to a similar extent between
day 0 (S1) and day 1 (S2) and between day 1 and day 2
(83). No decline in counts was seen in patients given
pyrazinamide, even though treatment was extended by a
third day. The error standard deviation from the analyses of
variance (the patients x days of interaction) was greatest for
the patients in the Rifater group and lowest in the
pyrazinamide group.
The EBA was calculated as (log" S1 count- log" S3
count)/2 and is therefore the fall in log" CFU/ml sputum/day.
The mean EBA values found in the treatment groups of the
present study are compared with those found in the Nairobi
study' in Table 11. The mean EBA for the combined tablet
Table I. Counts of viable M. tuberculosis in sputum collections
Viable count log,o CFU/ml sputum Error
Drug No. of patients 51 S2 S3 S4
Rifater 9 6.76 6.53 5.65
Ethambutol 9 6.96 6.78 6.47













Table 11. Early bactericidal activity of ethambutol, pyrazinamide and Rifater as estimated in Nairobi' and in the present study
Fall in 109'0 CFU/m[ sputum/day (No. of patients)
Present study
Drug Dose Nairobi mean Mean 95% confidence limits
Rifater 0.685' (4) 0.558 (9) 0.682 0.435
0.598t (28)
Ethambutol 25 mglkg 0.308 (4) 0.245 (9) 0.361 0.128
Pyrazinamide 2 g 0.044 (8) 0.004 (10) 0.032 -0.026
• Nairobi patients received sepame daiy doses of isoniazid 300 mg, rifampicin 12 mg!kg, pymzjnamide 2 9 and suepromycWl 1 g.
t Mean value fOI" Nairobi patients gIVen all combinations of isoniazid 300 mg with rifampicin 12 mgIkg andfOf pyrazinamide 2 g.
the same three drugs plus streptomycin, though it must be
remembered that streptomycin was thought to increase the
EBA when given with pyrazinamide, and 0.598 10910
CFU/mVday was the mean of all combinations of isoniazid
with rifampicin and/or pyrazinamide. The mean EBA for
ethambutol was lower at 0.245 log" CFU/mVday (± 0.046),
while pyrazinamide with an EBA of 0.003 log" CFU/mVday
(± 0.014) showed no apparent bactericidal activity during the
3-day treatment period. The estimates in the present study
on larger groups of patients are thus similar to those found
in the earlier Nairobi study. The standard deviations of the
variations between patients in EBA were 0.161 for the
combined tablet group, 0.152 for the ethambutol group and
0.041 for the pyrazinamide group. Similar results were
obtained in a previous study.4 The standard deviation for the
group given isoniazid alone was 0.19 and the tendency for
groups with a high EBA to have high standard deviations
was also found.
No associations were found between the EBA and the S,
viable count, the radiographic severity of disease, degree of
cavitation, or the weight, age or sex of the patient.
Discussion
The resutts obtained in the present study agreed well with
those obtained in Nairobi.2 Very low values for pyrazinamide
were found in both studies, though pyrazinamide was found
to kill bacilli slowly but steadily throughout the 14-day period
of the Nairobi study.' Ethambutol had a moderately high
EBA, similar to the Nairobi estimates for rifampicin and
p-aminosalicylic acid. No direct comparison can be made
for Rifater since this was not available at the time that the
Nairobi study was done. However, in the Nairobi study, all
combinations of isoniazid with other drugs gave values no
higher than the particularly high EBA found with isoniazjd
alone, suggesting that other drugs given with isoniazid,
except perhaps streptomycin, did not influence the EBA of
combinations. The EBA of Rifater in our study was similar to
the value for all combinations that did not include
streptomycin, and only slightly lower than the value for the
streptomycin-eontaining combination in the Nairobi study.
It is important to realise that during the first 2 days of
treatment EBA is directed against bacilli in the sputum that
arise from the very large bacterial population in cavity walls,
distant from any phagocytic cells and therefore
predominantly extracellular.s ThQse bacilli that are multiplying
rapidly are also those that are kiiled most rapidly by
bactericidal drugs and it is therefore their death that is
measured by EBA. The EBA thus estimates the activity of a
drug against rapidly dividing extracellular bacilli and is
closely related to the conventional in vitro measure of
bactericidal activity, viz. the fall in CFU counts during
exposure of a culture in the logarithmic phase of growth to a
drug. It can be used to compare the activities of different
doses of the ~ame drug or to compare closely related drugs,
each tested at several dose levelsY
There are two fundamental measures of the activity of an
antituberculosis drug: rts ability to prevent the emergence of
resistance to another drug and its sterilising activity.8 The
EBA is a measure of drug actiVity during the critical period
when drug-resistant mutants are most likely to be selected
from the large initial viable bacterial population. However,
the ability of a drug to prevent the emergence of resistance
is unlikely to be directly related to its EBA, since high
bactericidal activity is not essential or even desirable for
preventing resistance. Ability to prevent resistance might be
better measured by the extent to which the EBA is
maintained as the size of the drug dose is decreased, since
this would indicate whether the drug is active throughout the
different lesions within the lungs, despite variation in
penetration into the lesions or in local drug activity.
While appropriate measurement of the EBA may indicate
the value of a drug in preventing resistance, it does not
measure its sterilising activity, which is the ability of a drug
to kill persistent bacilli that are metabolicaJly inactive and
consequently survive drug action until the later stages of
treatment. These bacilli are not necessarily extracellular and
indeed, evidence from EBA studies with rifabutin3.~ and from
the known likelihood of a breakdown of immunity in AJOS
patients to cause reactivation of dormant organisms,
suggests that they are probably intracellular or at least
closely associated with immune effector cells. Sterilising
activity is measured by the relapse rate during follow-up
after chemotherapy has been completed and also by the
rate at which sputum cultures are converted at about 2
months after its start.1 It is of course of much greater
practical importance than the EBA since rt determines the
period that treatment must be given to obtain a satisfactorily
low relapse rate. There is little correlation between the EBA
and the sterilising activity of drugs.s Rifampicin and
pyrazinamide are therefore the most effective sterilising
drugs and the backbone of modern short-course regimens,
yet pyrazinamide has a very low EBA and rifampicin only a
moderate EBA. On the other hand, ethambutol has a
moderate EBA, as again demonstrated in this study, but has
no sterilising activity. It is therefore only of value in
preventing the emergence of drug resistance and not in
shortening the duration of treatment.
SAM} Volume 86 No. 2 February 1996
This study was supported by the South African Medical
Research Council. The authors thank the Medical
Superintendent of Tygerberg Hospital for permission to publish
and for considerable help in carrying out the study, Professor
Stephan Maritz for assistance with the statistical analysis,
Amour Venter for excellent technical assistance, and Professor
H. J. Koornhof for critical review of the manuscript.
REFERENCES
1. Yeager M, ucy J, Smitl'l LR, le MaJstre CA. Quantitative studies 01 mycobacterial
populations in sputum ;:l.nd saliva. Am Rev Respir Dis 1967; 95: 998-1004.
2. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity 01 drvgs
in patients with pulmonary tuberculosis. Am Reil Respir Dis 1980: 121: 939-949.
3. Ghan Sl, New WW, Ma WK, et al. The early bactericidal activity of rifabutin
measured by sputum viable counts in Hong Kong patlents wIth pullTl()<'\ary
tuberculosis. Tuberc Lung Dis 1992; 73: 33-38.
4. 5irgel FA, Boma FJH, Parkin DP, era!. The early bactericidal activity of rilabutin in
patients witl1 pulmonary tuberculosis measured by sputum viable counts.
A new method of drug assessment. J Antimicrob Chemother 1994: 32: 867-875.
5. t.rltchison DA- The Garrod lecture. Un<lerstanding the chemotherapy 01 tuberculosis
- current problems. J Anrimicrob Chemother 1992; 29: 477-493.
6. Mitchi50n OA. Basic mechanisms of chemotherapy. Chest 1979: 765: 771-781.
7. Mirchison CA Assessment of new sterilizing drugs for treating pulmonary
wberculosis by culture;:l.t 2 months. Am Rev Respir Dis 1993: 147: 1062-1053.
Accepted 24 May 1994.
Effect of an immunisation
campaign in Natal and
KwaZulu on vaccination
coverage rates, 1990 - 1991
J. J. Dyer, K. N. Naidoo, S. Knight, T. Mjekevu,
G. Munr<~, A. Robinson
In 1990 the Department of National Health and Population
Development of South Africa launched a nationwide
immunisation campaign targeted mainly at measles. In
order to measure the effect of the campaign on
vaccination coverage rates for children, pre- and post-
campaign vaccination coverage surveys were undertaken
using a modified Expanded Programme for Immunisation
technique, stratified for race and urban/rural residence.
The results in KwaZulu-Natai showed no significant
increase in measles vaccination coverage for any race rates
after the campaign {as documented by Road-ta-HeaJth
cams}. There was a decrease in cQverage of the black
population. However, when a history of measles vaccination
was accepted, the results showed an increase in coverage.
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The results calt into question the effectiveness of
immunisation campaigns as a strategy for raising
vaccination coverage levels, as well as their having a
sustained impact on the incidence of measles. Alternative
strategies, such as the strengthening and expansion of
existing primary health care services, should be
considered.
S Afr Med J 1996; 86: 158-161.
In 1990 the Department of National Health and Population
Development launched a nationwide immunisation campaign
aimed primarily at measles, but which also emphasised the
need to increase coverage rates of vaccination against all
the diseases of the Expanded Programme for Immunisation
(EPI).
Despite the progress of the EPI, only 59% of children
worldwide under 1 year of age were estimated to have
received the measles vaccine in 1988, and measles stilt
causes an estimated 1.5 million deaths per year. 1 Before the
campaign, coverage rates were estimated to be between
50% and 68% for the black population, and around 80% for
white and coloured children aged between 12 and 23
months." In 1989, the year before the campaign, 18 123
cases of measles were notified in South AfTica.3 This is
probably an underestimate of the actual number of cases,
not all having been notified; hence, the true incidence
cannot be ascertained. However, given the notification data,
estimates of annual incidence rates for blacks for 1989
varied from 1.9/100 000 in Bophuthatswana and 3.8/100 000
in the Orange Free State, to 72.9/100 000 in the Eastern
Cape and 86.9/100 000 in Lebowa. Case fatality rates varied
from 0.9% to 8.0% in the different regions.~ In most regions
the incidence appeared to be declining.
Because of the high childhood morbidity and mortality, the
national immunisation campaign of May/June 1990 was
launched. The intention was to reduce the incidence of
measles and in~crease vaccination coverage rates through a
high-profile campaign intended to direct attention and
resources to preventive health care and immunisation
services, thereby producing effects which would be
sustained after the campaign proper was over. In Kwazulu-
Natal the campaign took the fonn of widespread pUblicity to
encourage vaccination at existing facilities. The availability of
vaccinations was Increased through their being offered at all
times at clinics, mobile points and in hospital outpatient
departments, which had not preViously been the case. Few
extra service points were introduced and defaulters and
contacts were not followed up.
As. one measure of the effectiveness of the campaign, it
was deemed necessary to measure coverage rates in
children before and after vaccination to see if a significant
increase in coverage rates had occurred. The pre-campaign
survey was undertaken in 1990. The survey reported here is
the post-campaign survey, which aimed to ascertain the
level of vaccination coverage of children aged from 9
months to 21 months in Natal and Kwazulu after the
campaign, and to compare the levels with those recorded in
the pre-campaign survey of February 1990. The detailed
results of this survey have been reported elsewhere. S
